Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-05
2006-12-05
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S351000, C514S423000, C514S445000, C514S461000, C514S625000, C546S242000, C546S300000, C548S530000, C549S062000, C549S475000, C564S193000
Reexamination Certificate
active
07144897
ABSTRACT:
Disclosed are compounds of formula X,which are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising compounds of formula X and methods of preparing the compounds of formula X are also disclosed.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5720936 (1998-02-01), Wadsworth et al.
patent: 5721130 (1998-02-01), Seubert et al.
patent: 5744346 (1998-04-01), Chrysler et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5811633 (1998-09-01), Wadsworth et al.
patent: 5850003 (1998-12-01), McLonlogue et al.
patent: 5877015 (1999-03-01), Hardy et al.
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 5912410 (1999-06-01), Cordell
patent: 5942400 (1999-08-01), Anderson et al.
patent: 6191166 (2001-02-01), Audia et al.
patent: WO 98/22597 (1998-05-01), None
patent: WO 98/33795 (1998-08-01), None
patent: WO 99/64001 (1999-08-01), None
patent: WO 00/03819 (2000-01-01), None
patent: WO 00/17369 (2000-03-01), None
patent: WO 00/47618 (2000-08-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 01/10387 (2001-02-01), None
patent: WO 01/23533 (2001-04-01), None
patent: WO 01 53255 (2001-07-01), None
patent: WO 01 66564 (2001-09-01), None
patent: WO 01 70672 (2001-09-01), None
patent: WO 02/02506 (2002-01-01), None
Branalt J. et al., (1997)Tetrahedron Letters38(19):3483-3486.
International Search Report for International Application PCT/US 02/17698.
Hyafil, et al., “In Vitro and In Vivo Reversal of Multidrug Resistance by GF120918, an Acridonecarboxamide Derivate” Cancer Research, (1993) 53: pp. 4595-4602.
Dantzig et al., “Reversal of P-Glycoprotein—mediated Multidrug Resistance by a Potent Cyclopropyldibenzosuberane Modulator, LY335979” Cancer Research, (1996) 56: pp. 4171-4179.
Hussaine et al., “Identification of a Novel Aspartic Protease (Asp2) as β-Secretase” Mol Cell. Neurosci. (1999) 14: pp. 419-427.
Gould, “Salt selection for basic drugs” Int. J. Pharm. (1986) 33: pp. 201-217.
Getman, et al., “Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)—(Hydroxyethyl) urea Isostere” J. Med. Chem., (1993) 36: pp. 288-291.
Vasquez, et al., “Inhibitors of HIV-1 Protease Containing the Novel and Potent (R)—(Hydroxyethyl) sulfonamide Isostere” J. Med. Chem., (1995) 38: pp. 581-584.
Berge et al., “Pharmaceutical Salts” J. Pharm. Sci. (1977) 66(1): pp. 1-19.
Kang et al., “The precursor of Alzheimer's disease amyloid A-4 protein resembles a cell-surface receptor” Nature (1987) 325: pp. 733-736.
Kitaguchi et al., “Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity” Nature (1981) 331: pp. 530-532.
Arrowsmith et al, “Amino-Alcohol Dipeptide Analogues: a Simple Synthesis of a Versatile Isostere For the Development of Proteinase Inhibitors” Tetrahedron Letters, (1987) 28: pp. 5569-5572.
Shibata, et al., “An Expeditious Synthesis of (2R,3S)-3-tert-Butoxycarbonylamino-1isobutylamino-4phenyl-2-butanol, a Key Building Block of HIV Protease Inhibitors” Tetrahedron Letters, (1997) 38: pp. 619-620.
Vassar et al., “β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE” Science (1999) 286: pp. 735-741.
Yan et al., Membrane-anchored asparty1 protease with Alzheimer's disease β-secretase activity Nature (1999) 402: pp. 553-537.
Brown David L.
Fang Larry
Fobian Yvette M.
Freskos John
John Varghese
Davis Zinna N.
Elan Oharmaceuticals, Inc.
McDonnell Boehnen & Hulbert & Berghoff LLP
Pharmacia & Upjohn Co.
LandOfFree
Hydroxy alkyl amines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxy alkyl amines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxy alkyl amines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3683512